GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ENCell Co Ltd (XKRX:456070) » Definitions » Cash Flow from Others

ENCell Co (XKRX:456070) Cash Flow from Others : ₩-5 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is ENCell Co Cash Flow from Others?

ENCell Co's cash flow from others for the three months ended in Mar. 2025 was ₩-5 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-5 Mil.


ENCell Co Cash Flow from Others Historical Data

The historical data trend for ENCell Co's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENCell Co Cash Flow from Others Chart

ENCell Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Others
4,364.49 4,104.90 36,614.09 -6,185.41 682.95

ENCell Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only - 88.89 - - -4.94

ENCell Co Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5 Mil.

ENCell Co Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of ENCell Co's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


ENCell Co Business Description

Traded in Other Exchanges
N/A
Address
701 Yeongdong-daero, 11th floor, Gangnam-gu, Seoul, KOR
ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.

ENCell Co Headlines

No Headlines